Teva Pharmaceutical Industries Ltd. $TEVA Shares Acquired by Bellevue Group AG

Bellevue Group AG lifted its stake in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 1,357.0% during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 421,501 shares of the company’s stock after acquiring an additional 392,571 shares during the period. Bellevue Group AG’s holdings in Teva Pharmaceutical Industries were worth $7,064,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also recently modified their holdings of the company. Bourgeon Capital Management LLC grew its stake in shares of Teva Pharmaceutical Industries by 100.7% in the 2nd quarter. Bourgeon Capital Management LLC now owns 723,974 shares of the company’s stock valued at $12,134,000 after buying an additional 363,252 shares during the period. Amundi lifted its holdings in Teva Pharmaceutical Industries by 18.5% in the first quarter. Amundi now owns 678,758 shares of the company’s stock valued at $10,080,000 after acquiring an additional 105,846 shares during the last quarter. IFM Investors Pty Ltd grew its position in Teva Pharmaceutical Industries by 9.4% in the second quarter. IFM Investors Pty Ltd now owns 226,534 shares of the company’s stock worth $3,797,000 after acquiring an additional 19,447 shares during the period. Vontobel Holding Ltd. increased its stake in Teva Pharmaceutical Industries by 5.5% during the second quarter. Vontobel Holding Ltd. now owns 719,676 shares of the company’s stock worth $12,062,000 after acquiring an additional 37,455 shares during the last quarter. Finally, Jump Financial LLC raised its position in Teva Pharmaceutical Industries by 172.1% in the first quarter. Jump Financial LLC now owns 1,325,526 shares of the company’s stock valued at $20,373,000 after purchasing an additional 838,423 shares during the period. Hedge funds and other institutional investors own 54.05% of the company’s stock.

Insiders Place Their Bets

In related news, insider Mark Sabag sold 216,892 shares of the business’s stock in a transaction on Tuesday, December 9th. The shares were sold at an average price of $28.73, for a total transaction of $6,231,307.16. Following the completion of the transaction, the insider owned 52,828 shares in the company, valued at approximately $1,517,748.44. The trade was a 80.41% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Roberto Mignone sold 200,000 shares of the firm’s stock in a transaction on Thursday, November 6th. The shares were sold at an average price of $24.11, for a total value of $4,822,000.00. Following the completion of the sale, the director owned 495,000 shares in the company, valued at approximately $11,934,450. This represents a 28.78% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 532,360 shares of company stock worth $14,364,929 in the last 90 days. Corporate insiders own 0.49% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have weighed in on TEVA. Scotiabank started coverage on shares of Teva Pharmaceutical Industries in a research note on Friday, December 5th. They set a “sector outperform” rating and a $35.00 target price for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a research report on Wednesday, October 8th. The Goldman Sachs Group boosted their target price on Teva Pharmaceutical Industries from $28.00 to $31.00 and gave the company a “buy” rating in a research report on Monday, December 8th. JPMorgan Chase & Co. raised their price target on Teva Pharmaceutical Industries from $26.00 to $28.00 and gave the stock an “overweight” rating in a research report on Thursday, November 6th. Finally, Barclays began coverage on Teva Pharmaceutical Industries in a research note on Tuesday. They set an “overweight” rating and a $35.00 target price on the stock. Three analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Teva Pharmaceutical Industries has an average rating of “Buy” and a consensus target price of $30.25.

Teva Pharmaceutical Industries Stock Performance

Shares of TEVA opened at $29.80 on Friday. The stock has a 50-day simple moving average of $23.43 and a 200-day simple moving average of $19.60. The company has a debt-to-equity ratio of 2.31, a quick ratio of 0.82 and a current ratio of 1.11. Teva Pharmaceutical Industries Ltd. has a 1 year low of $12.47 and a 1 year high of $30.20. The stock has a market capitalization of $34.18 billion, a PE ratio of 49.67, a PEG ratio of 1.79 and a beta of 0.67.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.